The FMEC recommends reimbursement for trabectedin and doxorubicin in leiomyosarcoma, indicating conditions apply.
The Formulary Management Expert Committee (FMEC) recommends that trabectedin in combination with doxorubicin be reimbursed as first-line treatment for patients with advanced unresectable or metastatic uterine or soft tissue leiomyosarcoma, provided certain conditions are met. Trabectedin in combination with doxorubicin may be reimbursed for the treatment of adult patients aged 18 years or older with histologically confirmed leiomyosarcoma who have not previously received chemotherapy in the locally advanced or metastatic setting. A price reduction for trabectedin may be required.
No takes yet. Share an insight, caveat, or question.
CDA-AMC (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: